ALDX Aldeyra Therapeutics Inc.

6.21
-0.88  -12%
Previous Close 7.08
Open 5.2
Price To Book 2.18
Market Cap 170,716,322
Shares 27,490,551
Volume 3,733,343
Short Ratio
Av. Daily Volume 275,642

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 initiation announced April 2, 2019.
ADX-102 - topical ocular reproxalap - RENEW
Dry eye syndrome
Phase 3 data March 25, 2019 - primary endpoint met.
Reproxalap (ADX-102)
Allergic conjunctivitis
Phase 3 data did not meet endpoints - June 25, 2019.
ADX-102 reproxalap
Noninfectious anterior uveitis
Phase 3 initial data due in 2H 2019.
Reproxalap (ADX-102)
Sjögren-Larsson Syndrome (SLS)
Phase 2 trial to be initiated 2H 2019.
ADX-1612 (ganetespib)
Mesothelioma
Phase 3 trial to be initiated 2H 2019 with initial data due 2020.
ADX-2191
Proliferative vitreoretinopathy (PVR)

Latest News

  1. No Solace For Aldeyra As Late-Stage Study Of Lead Drug In Anterior Uveitis Fails
  2. Aldeyra shares slide 29% premarket after trial of eye disease treatment fails to meet goals
  3. Aldeyra Therapeutics Announces Results from the SOLACE Trial in Noninfectious Anterior Uveitis
  4. Aldeyra Therapeutics Schedules Webcast and Conference Call to Announce Top-Line Results from the SOLACE Trial in Noninfectious Anterior Uveitis
  5. Aldeyra Therapeutics to Participate in the Jefferies 2019 Global Healthcare Conference
  6. Edited Transcript of ALDX earnings conference call or presentation 9-May-19 12:00pm GMT
  7. Aldeyra Therapeutics Inc (ALDX) Q1 2019 Earnings Call Transcript
  8. Aldeyra Therapeutics Announces First Quarter 2019 Financial Results and Provides Corporate Update
  9. Aldeyra Therapeutics to Report First Quarter 2019 Financial Results and Host Conference Call on Thursday, May 9, 2019
  10. Aldeyra Therapeutics Announces Last Patient Dosed in the SOLACE Phase 3 Clinical Trial
  11. Aldeyra Therapeutics Announces Presentation of Phase 2b Dry Eye Disease Results at the 2019 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
  12. Aldeyra Therapeutics Announces First Patient Enrolled in the RENEW Phase 3 Clinical Trial for Dry Eye Disease
  13. Aldeyra's Eye Drug Meets Main Goal in Study, Shares Surge
  14. Future Brightens for 2 Small Biotech Stocks
  15. Here's Why Aldeyra Therapeutics Stock Soared as Much as 79.1% Today
  16. Aldeyra stock jumps 50 percent after eye allergy trial success
  17. Aldeyra's eye drug meets main goal in late-stage study, shares surge
  18. Should Aldeyra Therapeutics (NASDAQ:ALDX) Be Disappointed With Their 68% Profit?